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Qiliqiangxin capsule is newly developed Chinese patent drug and proved to be eﬀective and safe for the treatment of patients with
chronic heart failure. We compared the eﬀects of diﬀerent dose Qiliqiangxin on L type Ca2+ current (ICa-L) between normal and
hypertrophied myocytes. A total of 40 healthy Sprague—Dawley rats were used in the study. The rats were randomly divided into
two groups (control group and hypertrophy group). Cardiac hypertrophy was induced by pressure overload produced by partial
ligation of the abdominal aorta. The control group was the sham-operated group. After 1 month, cardiac ventricular myocytes
were isolated from the hearts of rats. Ventricular myocytes were exposed to 10 and 50μmol/L Qiliqiangxin, and whole cell patch-
clamp technique was used to study the eﬀects of Qiliqiangxin on ICa-L.T h ec u r r e n td e n s i t i e so fICa-L were similar in control group
(−12.70 ± 0.53pA/pF, n = 1 2 )a n di nh y p e r t r o p h yg r o u p( −12.39 ± 0.62pA/pF, n = 10). They were not statistically signiﬁcant.
10 and 50μmol/L Qiliqiangxin can decrease ICa-L peak current 48.6% ± 16.8% and 59.0% ± 4.4% in control group. However,
the peak current was only reduced 16.73% ± 8.03% by 50μmol/L Qiliqiangxin in hypertrophied myocytes. The inhibited action
of Qiliqiangxin on ICa-L of hypertrophy group was lower than in control group. Qiliqiangxin aﬀected L-type Ca2+ channel and
blocked ICa-L,a sw e l la sa ﬀected cardiac function ﬁnally. Qiliqiangxin has diphasic action that is either class IV antiarrhythmic
agent or the agent of eﬀect cardiac function.
1.Introduction
The traditional Chinese medicines have proven the safety
and eﬃciency of herbs in the management of some diseases
since ancient times. Qiliqiangxin capsule is newly developed
Chinese patent drug and proved to be eﬀective and safe
by phase 3 clinic trial for the treatment of patients with
chronic heart failure. It includes over 11 ingredients such
as Ginseng, Radix Astragali, Aconite Root, Salvia Miltior-
rhiza, and Semen Lepidii Apetali [1, 2]. Previous studies
showedQiliqiangxincapsulecanimproveheartfunctionand
decrease serum level of TNF-α and relieve inﬂammatory
cell inﬁltration of myocardium in rats with adriamycin
induced cardiomyopathy [3]. Nevertheless, the excitation-
contraction coupling in the cardiac myocyte is triggered by
the inﬂux of Ca2+ through L type Ca2+ channel and inducing
Ca2+ releasefromthesarcoplasmicreticulum[4,5].Blocking
Ca2+ channel and reducing Ca2+ overload will be of beneﬁt
in the progress of heart failure. Qiliqiangxin should aﬀect L
type Ca2+ channel and further alter cellular Ca2+ regulation
as well as eﬀect the heart function ﬁnally. We compared
the eﬀects of diﬀerent dose Qiliqiangxin on L type Ca2+
current (ICa-L) between normal and hypertrophied myocytes
and to comprehend the rational usage of Qiliqiangxin on
h y p e r t r o p h i e dm y o c y t e si nt h i ss t u d y .
2.MaterialandMethods
2.1. Vegetal Material. Qiliqiangxin consists of Ginseng,
Radix Astragali, Aconite Root, Salvia Miltiorrhiza, Semen2 Evidence-Based Complementary and Alternative Medicine
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Figure 1: The concentration-dependent manner of Qiliqiangxin on ICa-L in cardiac myocytes of rat (IC50 = 10.38μmol/L).
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Figure 2: The eﬀects of 10 and 50μmol/L Qiliqiangxin on ICa-L in normal and hypertrophied myocytes.
Lepidii Apetali, Cortex Periplocae Sepii Radicis, Rhizoma
Alismatis, Carthamus Tinctorius, Polygonatum Odorati,
Seasoned Orange Peel, and Rumulus Ginnamomi [3] (Yiling
Pharmaceutical Corporation, Shijiazhuang, China). The
drug powder was dissolved with sterile water at the concen-
tration of 2.67g/mL. 10μmoL/l and 50μmol/L Qiliqiangxin
were prepared for the study.
2.2. Study Models. A total of 40 healthy Sprague-Dawley rats
(9–11-week old, either sex, weight 210 to 300g) were used
in the study. All the rats used in the following experiments
were subject to the Guiding Principles for the Care and Use
of Laboratory Animals and the Recommendations from the
Declaration of Tongji University. The rats were randomly
divided into two groups (control group and hypertrophy
group). Cardiac hypertrophy was induced by pressure over-
load produced by partial ligation of the abdominal aorta by
using the method described by Anderson [6–8]. The control
group was the sham-operated group; the aorta was dissected
without application of the ligation. After operation, both
groups were fed up with normal fodder and tap water in
diﬀerent cages for one month.
2.3. Cardiac Ventricular Myocytes Isolation. Cardiac ven-
tricular myocytes were isolated from the hearts of rats
using previous protocols [9]. Brieﬂy, hearts were rapidly
excisedandcycloperfusedwithlowcalciumTyrode’ssolution
containing0.08%Collagenase,0.006%Protease,andthenget
single ventricular myocyte. The single ventricular myocyte
selected for study is rod shaped, had clear striations and
smooth and glossy surface.
2.4. Whole Cell Patch Clamp. We recorded Ca2+ current in
aN a +-free bath solution. To block outward K+ currents the
bath contained (mM): 120 CsCL, 2 CaCl2,10 TEA, 5 4-AP,
1M g C l 2, 5 HEPES, 5 Glucose. PH = 7.4( C s O H ) .T h e
patch pipettes (borosilicate glass, 1.5–3MΩ)w e r eﬁ l l e dw i t h
the pipette solution (mM): 120 CsCl, 1 CaCl2, 10 HEPES,
5M g - A T P ,1 0E G T A .P H = 7.2 (CsOH). All recordings
are at room temperature. The external solution was ﬁlled
with 95% O2 and 5% CO2.C a 2+ currents were elicited
by voltage steps from −90 to +55mV. Compensated series
resistance was 1.59 ± 0.20MΩ. Cell capacitance averaged
26.9±4.1pF(n = 10pergroup).Tonormalizefordiﬀerences
in total membrane area, current densities (in pA/pF) were
calculated by dividing the total current by the membrane
capacitance of the cell. Data were sampled at 10kHz and
ﬁltered at 2kHz by using an Axopatch 200A ampliﬁer (Axon
Instruments).
2.5. Statistical Analysis. pCLAMP 9.0 software was used
for data acquisition and analysis values are presented asEvidence-Based Complementary and Alternative Medicine 3
Table 1: The measurement of rats basic characteristics.
BW (g) HW (mg) LVW (mg) HW/BW (mg/g) LVW/BW (mg/g)
Control 237 ±23 730 ±26 507 ±48 2.67 ±0.10 2.01 ±0.15
Hypertrophy 229 ±18 810 ±15∗ 672 ±50∗ 3.43 ±0.15∗ 2.63 ±0.19∗
Notation. ∗P<0.05, compared to control group. BW: body weight, HW: heart weight, left ventricular weight: LVW.
means±S.D. Statistical comparisons between the diﬀer-
ent amiodarone concentrations groups were obtained by
ANOVA. Comparisons between control and hypertrophied
myocytes group means were performed with Student’s t-
test. Diﬀerences with P<0.05 were considered signiﬁcant,
completedbySPSS11.5Statisticallypackage.Concentration-
response relationships were ﬁt to the Hill equation to
determine the concentration of drug required for 50%
inhibition (IC50).
3. Results
3.1. Rats Characteristics. The rat hearts were signiﬁcantly
larger in hypertrophy group (810 ± 15mg, n = 22) than in
control group (730 ± 26mg, n = 18). However, there was
no diﬀerence in body weight between the two groups. Heart
weight index (heart weight/body weight, HW/BW) and
left ventricular weight index (left ventricular weight/body
weight, LVW/BW) in hypertrophy group were greater than
those in control group. They were statistically signiﬁcant
(Table 1).
3.2. Eﬀects of Qiliqiangxin on ICa-L. The current densities of
ICa-L were similar in control group (−12.70 ± 0.53pA/pF,
n = 12)andinhypertrophygroup(−12.39±0.62pA/pF,n =
10). They were not statistical signiﬁcant. Qiliqiangxin obvi-
ously decrease ICa-L of normal myocytes and represented a
concentration-dependent manner. Its IC50 was 10.38μmol/L
(Figure 1). 10 and 50μmol/L Qiliqiangxin can decreased
ICa-L peak current 48.6% ± 16.8% and 59.0% ± 4.4% in
control group. Interestingly, ICa-L represented insensitivity
for Qiliqiangxin in hypertrophied myocytes. The peak
current was only reduced 16.73% ± 8.03% by 50umol/L
Qiliqiangxin. Therefore, the inhibited action of Qiliqiangxin
on ICa-L of hypertrophy group was lower than in control
group (Figure 2).
4. Discussion
Cardiac hypertrophy is associated with a signiﬁcantly
increased risk of cardiovascular morbidity and mortal-
ity that were frequently induced by electrical remodeling
and arrhythmogenesis. The antiarrhythmic research was
most based on normal myocytes, and whether they have
same action on pathosis myocytes was unknown. As a
result,meansoftreatinghypertrophy-associatedarrhythmias
remain disappointingly ineﬀective. So far, there were four
main classes of antiarrhythmic agents. Class IV agents are
slow calcium channel blockers and decrease conduction
through the AV node. They shorten the plateau of the action
potential and reduce the contractility of the heart. Class IV
agents may be inappropriate in cardiac hypertrophy treat-
ment. Nevertheless, blocking Ca2+ channels and reducing
Ca2+ overload will be of beneﬁt in the progress of cardiac
hypertrophy.
In pressure overload hypertrophy models, we found that
the currents amplitude of ICa-L on hypertrophied myocytes
were higher than those in control. But the current densities
weresimilarbecauseoftheswellingvolumeofhypertrophied
myocytes.AcuteapplicationofQiliqiangxindoesinhibitICa-L
in normal cardiac myocytes. IC50 was 10.38μmol/L. 10 and
50μmol/L Qiliqiangxin can, respectively, decreased 48.6% ±
16.8% and 59.0% ± 4.4% of the peak current of ICa-L in
control group. To compare with the hypertrophy group, ICa-L
showed diﬀerent eﬀects of Qiliqiangxin. Interestingly, the
peakcurrentwasonlyreduced16.73%±8.03%by50μmol/L
Qiliqiangxin. The inhibited action of Qiliqiangxin on ICa-L of
hypertrophy group was lower than in control group. In other
words, ICa-L represented more insensitivity for Qiliqiangxin
in hypertrophied cardiac myocytes. Qiliqiangxin displayed
the insensitiveness that may be facilitated for its utilization
in cardiac hypertrophy and heart failure. Because it partly
blocked ICa-L and did not weaken myocardial contractil-
ity basically. 10μmol/L Qiliqiangxin obviously decreased
48.6%±16.8% of the peak current of ICa-L in normal cardiac
myocytes, which made it reserve antiarrhythmic activity as
class IV agents. That also signiﬁes we should deal with
diﬀerence between hypertrophied heart and normal heart
when we use Qiliqiangxin in the clinic.
Qiliqiangxin includes over 11 ingredients. The mech-
anism of the antiarrhythmic action is complex and not
c o m p l e t e l yu n d e r s t o o d .I ti sh a r dt op r o v ew h i c hh e r bh a s
mainly contributed to the eﬀect on L type Ca2+ channel.
Recently, ShenSongYangXin capsule, a traditional Chinese
herb, has been reported to eﬀectively block ICa-L [10]. Zhao
et al. had reported that Radix Astragali eﬀectively protected
against cardiac dysfunctional and morphological aberrations
in experimental myocardial infarction [11]. Aconite Root
was proved to have positive inotropic, positive chronotropic,
vasodilation, and diuretic eﬀects in the management of
congestive heart failure [12]. Qiliqiangxin is composed of
Radix Astragal, Aconite Root and parts of Shensong Yangxin
which are the main active constituents of Qiliqiangxin. In
the cardiac function, the excitation-contraction coupling
of cardiac myocyte is triggered by Ca2+ inﬂux through L-
type Ca channels [4, 5]. Ca2+ inﬂux activates calmodulin
kinase that may activate transcription factors and cAMP
response element binding protein (CREB). CREB promoted
several cytokine secretions such as interleukin-10 (IL-10)
[13, 14]. Inﬂammatory cytokines mainly derived from
cardiac myocytes were involved in the progression of heart
failure [15]. A proinﬂammatory cytokine (TNF-α)h a sb e e n4 Evidence-Based Complementary and Alternative Medicine
linked to accelerate myocardial necrosis and deteriorated
cardiac function. Serum level of TNF-α in patients with
chronic heart failure increased and correlated with poor
cardiac performance [16]. IL-10 and TNF-α induced left
ventricular remodeling and dysfunction in the failing heart
[17]. Qiliqiangxin may improve cardiac function of rats with
MIthroughregulationthebalancebetweenTNF-αandIL-10
[3]. Blocking Ca2+ channels and reducing Ca2+ inﬂux as well
as weakening myocardial contractility will be the key point
in the progress of cardiac hypertrophy and heart failure. The
mechanism underlying the beneﬁcial eﬀects of Qiliqiangxin
may involve the regulation of Ca2+ channel and reduce Ca2+
inﬂux. Meantime, it inﬂuences several cytokine secretions
indirectly. We concluded Qiliqiangxin aﬀected L-type Ca2+
channelandblockedICa-L,aswellasaﬀectedcardiacfunction
ﬁnally. Qiliqiangxin has diphasic action that is either class IV
antiarrhythmic agent or the agent of eﬀect cardiac function.
4.1. Study Limitations. This study was focused on the eﬀect
of Qiliqiangxin in ICa-L. Further studies should be on the
regulation of Na+ and K+ channels.
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